Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Myogen has achieved its target enrollment of 186 patients in ARIES-1, one of the company's two pivotal phase III trials of ambrisentan in patients with pulmonary arterial hypertension.
Subscribe to our email newsletter
A number of additional patients are in screening and the company will allow those patients to complete the process and be either randomized into the trial or disqualified, in accordance with the trial protocol.
The company expects to report top line results of the trial in the second quarter of 2006. And it expects to report top line results of ARIES-2, the other pivotal phase III trial of ambrisentan in pulmonary arterial hypertension (PAH), in December of this year.
“Based on the properties of the compound and the results of our phase II trial, we believe ambrisentan’s efficacy and safety profile may position it as the best-in-class among endothelin receptor antagonists,” said William Freytag, president and CEO of Myogen.